{"filing":{"accession_number":"0001104659-26-093466","cik":"0001768946","ticker":null,"company_name":"Biophytis SA","form":"6-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"tm2621688d2_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1768946/000110465926093466/tm2621688d2_6k.htm"},"events":[{"id":26733,"run_id":24307,"accession_number":"0001104659-26-093466","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Biophytis announces regulatory approval from Brazil's ANVISA to conduct the Phase 2 OBA clinical trial for obesity, a material operational and clinical milestone. The disclosure describes approval of a multi-regional clinical development program, partnership arrangements with Blanver and EMBRAPII, and the company's strategic expansion into a second indication (obesity) alongside its primary indication (sarcopenia). This is a significant clinical and operational development that would affect a reasonable investor's assessment of the company's pipeline progress and market opportunity, but does not fit the specific event categories of earnings release, M\u0026A activity, or other named types.","company_name":"Biophytis SA","ticker":null,"filing_date":"2026-08-10","form":"6-K","submitted_at":null,"items":[{"id":27959,"accession_number":"0001104659-26-093466","item_number":"EX-99.1","item_title":"tm2621688d2_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Biophytis announces regulatory approval from Brazil's ANVISA to conduct the Phase 2 OBA clinical trial for obesity, a material operational and clinical milestone. The disclosure describes approval of a multi-regional clinical development program, partnership arrangements with Blanver and EMBRAPII, and the company's strategic expansion into a second indication (obesity) alongside its primary indication (sarcopenia). This is a significant clinical and operational development that would affect a reasonable investor's assessment of the company's pipeline progress and market opportunity, but does not fit the specific event categories of earnings release, M\u0026A activity, or other named types.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-11T00:09:16.610977+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27959,"accession_number":"0001104659-26-093466","item_number":"EX-99.1","item_title":"tm2621688d2_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Biophytis announces regulatory approval from Brazil's ANVISA to conduct the Phase 2 OBA clinical trial for obesity, a material operational and clinical milestone. The disclosure describes approval of a multi-regional clinical development program, partnership arrangements with Blanver and EMBRAPII, and the company's strategic expansion into a second indication (obesity) alongside its primary indication (sarcopenia). This is a significant clinical and operational development that would affect a reasonable investor's assessment of the company's pipeline progress and market opportunity, but does not fit the specific event categories of earnings release, M\u0026A activity, or other named types.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-11T00:09:16.610977+00:00","company_name":"Biophytis SA","ticker":null,"filing_date":"2026-08-10"}]}